

Staphylococcus aureus (702): sc-58036

BACKGROUND

Staphylococcus aureus is a Gram-positive coccus that frequently lives on the skin or in the nose of humans. This microbe produces β -lactamase, enzymes which break down the β -lactam ring of the penicillin molecule, making it resistant to most penicillin and cephalosporins. *Staphylococcus aureus* causes a broad range of illnesses, from minor skin infections and abscesses to life-threatening diseases such as pneumonia, meningitis, endocarditis, septicemia and Toxic Shock Syndrome (TSS). Toxic Shock Syndrome Toxin-1 (TSST-1) is a staphylococcal secreted exotoxin that is responsible for TSS, since it leads to non-specific binding of MHC II with T cell receptors, resulting in polyclonal T cell activation. TSST-1 also plays a role in the pathogenesis of several autoimmune and allergic diseases associated with B cell hyperactivity, and it produces antagonistic effects on IL-4-induced IgE synthesis. Symptoms of TSS include high fever, accompanied by low blood pressure, malaise and confusion, which can rapidly progress to stupor, coma and multi-organ failure.

REFERENCES

- Curran, J.P. and Al-Salihi, F.L. 1980. Neonatal staphylococcal scalded skin syndrome: massive outbreak due to an unusual phage type. *Pediatrics* 66: 285-290.
- Hofer, M.F., Newell, K., Duke, R.C., Schlievert, P.M., Freed, J.H. and Leung, D.Y. 1996. Differential effects of Staphylococcal Toxic Shock Syndrome Toxin-1 on B cell apoptosis. *Proc. Natl. Acad. Sci. USA* 93: 5425-5430.
- Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. and Tenover, F.C. 1997. Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *J. Antimicrob. Chemother.* 40: 135-136.
- Jabara, H.H. and Geha, R.S. 1997. The superantigen Toxic Shock Syndrome Toxin-1 induces CD40 ligand expression and modulates IgE isotype switching. *Int. Immunol.* 8: 1503-1510.
- Chambers, H.F. 2001. The changing epidemiology of *Staphylococcus aureus*? *Emerg. Infect. Dis.* 7: 178-182.
- Chang, S., Sievert, D.M., Hageman, J.C., Boulton, M.L., Tenover, F.C., Downes, F.P., Shah, S., Rudrik, J.T., Pupp, G.R., Brown, W.J., Cardo, D., Fridkin, S.K.; Vancomycin-Resistant *Staphylococcus aureus* Investigative Team. 2003. Infection with vancomycin-resistant *Staphylococcus aureus* containing the vanA resistance gene. *N. Engl. J. Med.* 348: 1342-1347.
- Buonpane, R.A., Moza, B., Sundberg, E.J. and Kranz, D.M. 2005. Characterization of T cell receptors engineered for high affinity against Toxic Shock Syndrome Toxin-1. *J. Mol. Biol.* 353: 308-321.
- Parsonnet, J., Hansmann, M.A., Delaney, M.L., Modern, P.A., Dubois, A.M., Wieland-Alter, W., Wissemann, K.W., Wild, J.E., Jones, M.B., Seymour, J.L. and Onderdonk, A.B. 2005. Prevalence of Toxic Shock Syndrome Toxin 1-producing *Staphylococcus aureus* and the presence of antibodies to this superantigen in menstruating women. *J. Clin. Microbiol.* 43: 4628-4634.

SOURCE

Staphylococcus aureus (702) is a mouse monoclonal antibody raised against UV-inactivated *Staphylococcus aureus* cells.

PRODUCT

Each vial contains 100 μ g IgG₃ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Staphylococcus aureus (702) is recommended for detection of *Staphylococcus aureus*, Protein A-negative *Staph. aureus* and *Staph. epidermidis* by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with *Streptococcus sp.*, *Mycoplasma sp.* or *Corynebacteria sp.*

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.